Blood Stopper (Ankaferd)
Phase 3Small molecule
Blood Stopper (Ankaferd) is one of 9 small molecule programs targeting Epistaxis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in Epistaxis
#DrugCompanyPhaseTrials
1Avastin
RocheApproved
Cyklokapron
JJ Molner
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bactroban
PPadagis LLC
Approved
Blood Stopper (Ankaferd)
AAnkara Ataturk Sanatorium Training and Research Hospital
Phase 3
Silver Nitrate
MMansoura University Hospital
Preclinical
Trichloroacetic Acid
IIndonesia University
Preclinical
Floseal
UUnity Health Toronto
Preclinical
Thrombin JMI
UUniversity of Kansas Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Epistaxis1 trial
Tranexamic Acid Versus Blood Stopper Treatments in Epistaxis Management
Not yet recruiting·—·Phase 4·NCT06490653·186 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Blood Stopper (Ankaferd). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details